Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)

Korean Multiple Myeloma Working Party

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m 2 ) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935

    Original languageEnglish
    Pages (from-to)923-929
    Number of pages7
    JournalBiology of Blood and Marrow Transplantation
    Volume24
    Issue number5
    DOIs
    Publication statusPublished - 2018 May

    Keywords

    • Autologous transplantation
    • Intravenous busulfan
    • Melphalan
    • Multiple myeloma

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Fingerprint

    Dive into the research topics of 'Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)'. Together they form a unique fingerprint.

    Cite this